linjc16/ctgov huggingface dataset:
Observing the Relationship of Fibroblast Growth Factor and Fibroblast in Thyroid Eye Disease

Study Overview
=================
Brief Summary
-----------------
Graves' orbitopathy (GO) affects about 50% of patients with Graves' disease (GD), and some cannot be cured by current treatments. Orbital fibroblasts involves in the pathogenesis of GO by producing glycosaminoglycans and inflammatory cytokines. Since fibroblast growth factors (FGFs) binding to FGF receptors (FGFRs) can induce proliferation and differentiation of fibroblasts, investigators would like to measure the expression of FGFs and FGFRs in GO patients to see if inhibition of FGF-FGFR pathway has potential in treatment.

Official Title
-----------------
Observing the Relationship of Fibroblast Growth Factor and Fibroblast in Thyroid Eye Disease

Conditions
-----------------
Graves Ophthalmopathy

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: diagnosed as thyroid eye disease suggested to accept orbital decompression Exclusion Criteria: age below 20 or above 80 pregnancy

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum concentration of selected growth factors | Investigators would like to measure fibroblast growth factors concentration (ug/mL) by ELISA according to the manufacturers' instruction | 1 year | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| RNA expression level of selected growth factor receptors | Investigators would like to measure growth factor receptors expression level comparing to house-keeping gene using real-time PCR | 1 year | 
| RNA expression level of selected growth factor receptors | Investigators would like to measure adipogenesis-related genes expression level comparing to house-keeping gene using real-time PCR | 1 year | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Fibroblast growth factors, Fibroblast growth factors receptors, Thyroid orbitopathy
An Extension of the TG1101-RMS201 Trial

Study Overview
=================
Brief Summary
-----------------
This study evaluates the long term use of a single agent ublituximab, a novel monoclonal antibody, in patients with relapsing forms of multiple sclerosis

Official Title
-----------------
An Open Label Extension of the TG1101-RMS201 Trial, for Subjects Currently Enrolled in TG1101-RMS201Treated With Ublituximab for Relapsing Forms of Multiple Sclerosis

Conditions
-----------------
Relapsing Remitting Multiple Sclerosis

Intervention / Treatment
-----------------
* Biological: Ublituximab


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Subjects currently enrolled in TG1101-RMS201 trial Subjects who have completed three infusions of ublituximab (at Day 1, Day 15, and Week24, as specified in the TG1101-RMS201 protocol) and have completed the scheduled assessments up to the final 48-week visit Exclusion Criteria: Subjects who discontinued ublituximab treatment or withdrew consent from the TG1101- RMS201 study during the 48-week evaluation period Subjects who have started any other immunomodulating or disease modifying therapy after completion of the TG1101-RMS201 trial Pregnant or nursing mothers

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Ublituximab<br>Ublituximab IV infusions on Weeks 1E, 24E, 48E, 72E and (6E | Biological: Ublituximab<br>* Enrolled Subjects will be infused with ublituximab on Weeks 1E, 24E, 48E, 72E and 96E<br>* Other names: TG1101;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of participants with treatment-related events as assessed by CTCAE V4.0 | to determine the incidence of adverse events and any abnormal laboratory values | 96 weeks on therapy | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluate the % of participants with relapses |  | up to 96 Weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Relapsing Multiple Sclerosis
Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia

Study Overview
=================
Brief Summary
-----------------
Assess the immunotherapy benefit of interleukin-2 in acute myelogenous leukemia treatment during lymphocyte recovery.

Detailed Description
-----------------
Upon lymphocyte recovery after myeloablative induction standard chemotherapy pulse Interleukin-2 administered

Official Title
-----------------
Phase II Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia

Conditions
-----------------
Acute Myelogenous Leukemia

Intervention / Treatment
-----------------
* Drug: Interleukin-2


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Confirmed hematopathology diagnosis of AML receiving marrow suppressive treatment Total WBC recovery of 500 mm3 prior to IL-2 treatment Platelet count of at least 20,000 mm3 prior to starting IL-2 treatment Active infection controlled prior to starting IL-2 treatment Stable systolic blood pressure > 90mm Hg prior to starting IL-2 treatment O2 saturation >90% prior to starting treatment Stable cardiopulmonary status prior to starting IL-2 treatment Serum creatinine < or equal to 2.0 mg/dl Total bilirubin and AST <3x upper limits normal Exclusion Criteria: Acute Promyelocytic Leukemia Active thrombocytopenic bleeding Cardiac ejection fraction below 45% Pregnancy and/or lactation

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: interleukin-2<br>interleukin-2 therapy during lymphocyte recovery | Drug: Interleukin-2<br>* Famotine 20mg IV push daily just prior to the aldesleukin (IL-2) IL-2 18 million IU/m2 in 50 mL 5% D5 or NS IVPB over 15 - 30 minutes daily for 5 days<br>* Other names: pulse;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Event-free Survival | Event-free survival (EFS) = all patients; measured from the date of entry onto study until treatment failure, AML relapse, or death | 3 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
acute myelogenous leukemia, interleukin-2
HFNC and Prone Positioning in Awake Patients With Severe COVID-19

Study Overview
=================
Brief Summary
-----------------
The investigators evaluate the effects of High-flow nasal cannula (HFNC) in association with prone in patients with Covid-19 severe ARF.

Detailed Description
-----------------
The investigators evaluate the effects of High-flow nasal cannula (HFNC) in association with prone in patients with Covid-19 severe ARF. All patients with ARF related to Covid-19 and admitted to the ICU are turned in prone position whenever tolerated, while receiving oxygenation with HFNC. Outcomes of interest are the rate of success or failure (defined as the need for intubation and mechanical ventilation)

Official Title
-----------------
Effectiveness of High-flow Nasal Cannula and Prone Positioning in Awake Patients With COVID-19 and Severe Acute Respiratory Failure

Conditions
-----------------
Hypoxemic Respiratory Failure

Intervention / Treatment
-----------------
* Procedure: prone position


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: aged ≥18 years, admitted to the medical ICU for confirmed Covid-19 and acute hypoxemic respiratory failure Exclusion Criteria: patients already intubated at admission or those requiring immediate intubation
Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| HFNC/prone<br>awake patients with COVID-19 and severe acute respiratory failure receiving HFNC in prone position | Procedure: prone position<br>* patients are returned from prone to supine position while receiving oxygenation through HFNC<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of patients without intubation | successful oxygenation without intubation | through study completion, an average of 28 days |
Specific Molecular Imaging of DX600 Labeled by PET Radionuclide Targeting ACE2 in Patients

Study Overview
=================
Brief Summary
-----------------
Angiotensin-converting enzyme 2 (ACE2) plays an important role in renin-angiotensin system (RAS) and has been reported to relate with cancer. Recently, it has also been proved as the key target for COVID-19 infection. DX600 is a polypeptide that can specific binding to ACE2 specifically with nanomolar affinity reported in literature. This study constrcuted a radio-tracer, DX600 Labeled by PET Radionuclide, to monitoring biodistribution ACE2 in human beings, evaluate the detection ability of radio-tracer in ACE2 over-expression tumors and dynamic changes of ACE2 expression under therapy.

Official Title
-----------------
Specific Molecular Imaging of DX600 Labeled by PET Radionuclide Targeting ACE2 in Patients

Conditions
-----------------
Solid Tumor

Intervention / Treatment
-----------------
* Other: 68Ga-DX600 PET/CT


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age 18-75 years old; both sex; ECoG 0 or 1; Patients that would undergo biopsy or surgical operation with high ACE2 expression tumors such as colorectal cancer, renal cancer, pancreatic cancer, gastric cancer, liver cancer, lung cancer, brain cancer or suspected tumor. use 18F-FDG PET/CT as baseline evaluation Exclusion Criteria: Significant hepatic or renal dysfunction; Is Pregnant or ready to pregnant; Cannot lie on their back for half an hour; Suffering from claustrophobia or other mental diseases; Refusal to join the clinical study;

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 75 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Diagnostic
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Imaging cohort<br>All study participants will be allocated to this arm (single-arm study).Study participants will undergo 68Ga-DX600 PET/CT scans | Other: 68Ga-DX600 PET/CT<br>* DX600, labeled with 68Ga will be used as a molecular imaging tracer for PET/CT scanning<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| SUV | The uptake of uptake of the tracer in the primary and metastatic tumor lesions by measuring standardized uptake value（SUV） | 2 years |
Use of Arimidex and Zoladex as Pretreatment to IVF in Women With Ovarian Endometriosis

Study Overview
=================
Brief Summary
-----------------
Does a combination of Arimidex and Zoladex make endometriomas shrink and how is the following IVF outcome

Conditions
-----------------
Endometriosis

Intervention / Treatment
-----------------
* Drug: Combined treatment with Arimidex and Zoladex before IVF


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Endometrioma(s)with a size of 20-70 mm, persisted for at least 3 cycles Couples with indication and wish for IVF/ICSI Age of women: 20-40 years Regular menstrual cycle within normal range (21-35 days) Body Mass Index (BMI): 18-30 kg/m2 Exclusion Criteria: History with osteoporosis, liver-, kidney- or heart disease or thromboembolic disease Treatment of endometriosis with GnRH agonist during the last 3 month

Ages Eligible for Study
-----------------
Minimum Age: 20 Years
Maximum Age: 40 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Intervention/Treatment |
| --- |
|Drug: Combined treatment with Arimidex and Zoladex before IVF|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| size of endometriomas after 2½ month of combined downregulation |  |  |
Cosmetic Outcome, Patient-reported Outcomes, and Reconstruction-related Complications in Breast Cancer Women Treated With or Without Post-mastectomy Radiation Therapy

Study Overview
=================
Brief Summary
-----------------
This study aim to investigate the breast reconstruction outcome after mastectomy with or without radiation therapy from the patient's point of view.

Official Title
-----------------
Cosmetic Outcome, Patient-reported Outcomes, and Reconstruction-related Complications in Breast Cancer Women Treated With or Without Post-mastectomy Radiation Therapy: Prospective Cohort Study

Conditions
-----------------
Breast Cancer Female

Intervention / Treatment
-----------------
* Procedure: Breast reconstructive surgery


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Pathologically confirmed invasive breast carcinoma Women who underwent mastectomy and breast reconstruction Good performance status (ECOG 0-1) Exclusion Criteria: Recurrent breast cancer History of ipsilateral breast irradiation

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Procedure: Breast reconstructive surgery|All sorts of breast reconstructive surgery are allowed in this study in terms of timing, autologous/prosthetic and so forth.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Change from baseline of Breast-Q questionnaire score | Patient reported outcome measures include psychosocial functioning, patient treatment satisfaction, physical functioning, body image and pain. (Breast-Q survey) | Before mastectomy & reconstruction surgery (allowed up to 8 weeks ago) | 
| Change from baseline of Breast-Q questionnaire score | Patient reported outcome measures include psychosocial functioning, patient treatment satisfaction, physical functioning, body image and pain. (Breast-Q survey) | Immediate after the last reconstructive procedures/surgery (allowed plus 8 weeks) | 
| Change from baseline of Breast-Q questionnaire score | Patient reported outcome measures include psychosocial functioning, patient treatment satisfaction, physical functioning, body image and pain. (Breast-Q survey) | 1 year after the last reconstructive procedures/surgery (allowed plus 8 weeks) | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Reconstruction complications | Patient reported outcome measures include psychosocial functioning, patient treatment satisfaction, physical functioning, body image and pain. (Breast-Q survey) | within 1 year after last reconstruction procedures (plus 8 weeks) |
Risk and Protective Factors of Children and Adolescents Who Were Hospitalized Due to Alcohol Intoxication

Study Overview
=================
Brief Summary
-----------------
The aim of the study is to improve the prognosis of the development of alcohol consumption by considering a variety of biological, psychological and social risk and protective factors. Therefore, young people who have been hospitalized due to acute alcohol intoxication within the past 5 to 12 years will be interviewed in order to assess aspects of healthy or impaired psychosocial development. The study will also include a control group of young adults who were in hospital due to other medical conditions. The identification of relevant cases will be based on medical records of several children's hospitals. These records will be analysed with regard to potential predictors of developmental hazards and protective factors.

Official Title
-----------------
Prediction and Detection of Intermediate and Long-term Developmental Hazards in Adolescents After Alcohol Intoxication

Conditions
-----------------
Alcohol Use Disorders

Participation Criteria
=================
Eligibility Criteria
-----------------
experimental group: Inclusion Criteria: male and female volunteers who were hospitalized due to acute alcohol intoxication from January 1, 2000 to December 31, 2006 written informed consent by the subject minimum age of 20 years Exclusion Criteria: incapability to conduct interview control group: Inclusion Criteria: male and female volunteers who were hospitalized due to other medical conditions but not acute alcohol intoxication from January 1, 2000 to December 31, 2006 written informed consent by the subject minimum age of 20 years Exclusion Criteria: incapability to conduct interview

Ages Eligible for Study
-----------------
Minimum Age: 20 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Alcohol intoxicated adolescents<br>Adolescents who were hospitalized due to acute alcohol intoxication | |
| Control group<br>adolescents who were hospitalized due to other medical conditions but not alcohol intoxication | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Alcohol Use Disorders | Alcohol Use Disorders as measured by the The Alcohol Use Disorders Identification Test | 5 to 13 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Self-efficacy |  | 5 to 13 years | 
| Life Satisfaction |  | 5 to 13 years |
The Effect of Acupressure and Yoga on Premenstrual Symptoms and Quality of Life

Study Overview
=================
Brief Summary
-----------------
The research was carried out to determine the effect of acupressure and yoga applied to cope with PMS on premenstrual symptoms and quality of life.

Official Title
-----------------
The Effect of Acupressure and Yoga on Premenstrual Symptoms and Quality of Life in Coping With PMS

Conditions
-----------------
Premenstrual Syndrome, Nursing Caries

Intervention / Treatment
-----------------
* Other: ACUPRESSURE


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: have regular menstrual cycle Exclusion Criteria: Has a psychiatric diagnosis, Having any gynecological disease (anornal uterine bleeding, fibroids, ovarian cyst etc.) Using contraceptive drugs, With tissue deformity in its extremities, Any health problems that may prevent physical exercise

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Other
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: acupressure<br> | Other: ACUPRESSURE<br>* Acupressure points were determined in a certain order considering the direction of the meridian. The order of application was in the form of Spleen 6th point (SP 6) and 4 point of the Large Intestine (Li 4). In total, 4 points in the upper / lower extremities and 6 acupressure points along with parallel points were studied in each attempt.<br>* Other names: YOGA;|
| Experimental: music<br> | Other: ACUPRESSURE<br>* Acupressure points were determined in a certain order considering the direction of the meridian. The order of application was in the form of Spleen 6th point (SP 6) and 4 point of the Large Intestine (Li 4). In total, 4 points in the upper / lower extremities and 6 acupressure points along with parallel points were studied in each attempt.<br>* Other names: YOGA;|
| No Intervention: control<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| premenstrual syndrome scale |  | 12 weeks | 
| WHOQOL-BREF-TR |  | 12 weeks | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
PMS,, YOGA, NURSING, HEALTH QUALITY